Though BioMarin’s portfolio comprises eight marketed products, its top line is likely to have been driven by key drugs Voxzogo, Naglazyme and Vimizim. Since its commercial launch in 2021 ...

Now moving over to our enzyme therapies. Global demand drove strong results across all of BioMarin's marketed products. Double-digit PALYNZIQ revenue growth in the quarter was the result of ...

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim ...

BioMarin’s revenue largely comes from a few key products, notably Voxzogo and enzyme therapies. It has achieved strong growth through regulatory approvals and market expansion initiatives ...

BioMarin Pharmaceutical (NASDAQ:BMRN) is a biopharmaceutical company specializing in developing and commercializing innovative therapies for rare genetic disorders, with key products addressing ...

BioMarin's has signed the first contract with ... 92% of patients still had no need to take prophylactic Factor VIII replacement products at that timepoint, reinforcing the durability of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.